Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022

Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022

Paris, France, August 11, 2022 – 19:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend virtually the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place on Wednesday 17 August, 2022.

The conference will feature company presentations, one-on-one investor meetings and networking opportunities. Registration for the event is open here. To request a one-on-one meeting with Lloyd Diamond, please contact [email protected].

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision  

Contacts

You May Also Be Interested In

• First Orion Elevates Joe Stinziano to President and CEO; Charles Morgan to Uphold Key Roles as Chairman of the Board and Executive Committee
• OCOchem Advances Hydrogen Formate Electrolyzer Process By 10x To Create World’s Largest Industrial Scale CO2 Electrolyzer Cell
• Three-quarters of New Jerseyans Familiar With Proper Guidelines to Store and Dispose of Medications, Opioids and Edibles